Bone Loss After Denosumab: Only Partial Protection with Zoledronate

被引:89
|
作者
Reid, Ian R. [1 ,2 ,3 ]
Horne, Anne M. [1 ]
Mihov, Borislav [1 ]
Gamble, Gregory D. [1 ]
机构
[1] Univ Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand
[2] Auckland Dist Hlth Board, Dept Endocrinol, Auckland, New Zealand
[3] Univ Auckland, Fac Med & Hlth Sci, Private Bag 92019, Auckland, New Zealand
关键词
Osteoporosis; Denosumab; Bisphosphonates; Zoledronate; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; CONTROLLED-TRIAL; ANTIRESORPTIVE ACTIVITY; DISCONTINUATION; OSTEOPOROSIS; PREVENTION; MASS;
D O I
10.1007/s00223-017-0288-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A case series of six women with postmenopausal osteoporosis who had received continuous denosumab for 7 years and were then given a single infusion of zoledronate (5 mg) is reported. During denosumab treatment, bone mineral density (BMD) in the spine increased 18.5% (P = 0.006), and total hip BMD by 6.9% (P = 0.03). Post-zoledronate BMDs were measured 18-23 months after treatment, and there were significant declines at each site (P (spine) = 0.043, P (hip) = 0.005). Spine BMD remained significantly above the pre-denosumab baseline (+9.3%, P = 0.003), but hip BMD was not significantly different from baseline (-2.9%). At the time of post-zoledronate BMD measurements, serum PINP levels were between 39 and 60 mu g/L (mean 52 mu g/L), suggesting that the zoledronate treatment had not adequately inhibited bone turnover. It is concluded that this regimen of zoledronate administration is not adequate to preserve the BMD gains that result from long-term denosumab treatment.
引用
收藏
页码:371 / 374
页数:4
相关论文
共 50 条
  • [21] ZOLEDRONATE AS A PREVENTATIVE MEASURE FOR BONE LOSS FOLLOWING DENOSUMAB DISCONTINUATION: RESULTS FROM A MULTI-INSTITUTIONAL RANDOMIZED CONTROLLED TRIAL
    Fu, S. -H.
    Lee, C. -C.
    Hung, C. -C.
    Li, C. -Y.
    Wang, C. -Y.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S72 - S72
  • [22] PREVENTING POST-DENOSUMAB BONE LOSS WITH ZOLEDRONATE: A RANDOMIZED TRIAL IN POSTMENOPAUSAL WOMEN WITHOUT AND WITH PRE-EXPOSURE TO BISPHOSPHONATES
    Ferrari, S.
    Hars, M.
    Biver, E.
    Uebelhart, B.
    Joly, A. -C.
    Herrmann, F.
    Meier, C.
    Lippuner, K.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S293 - S294
  • [23] Zoledronate bone protection and anti-tumor effects
    不详
    UROLOGE, 2010, 49 (12): : 1580 - 1580
  • [24] Oral vs Intravenous Bisphosphonates for Preventing Bone Loss After Denosumab Discontinuation
    Dickens, Laura
    Vokes, Tamara
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 182 - 183
  • [25] Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting
    Everts-Graber, Judith
    Reichenbach, Stephan
    Gahl, Brigitta
    Haeuselmann, HansJoerg
    Ziswiler, Hans-Rudolf
    Studer, Ueli
    Lehmann, Thomas
    BONE, 2022, 163
  • [26] Prevention of post-bone marrow transplantation bone loss with zoledronate
    Arabi, A
    Bazarbachi, A
    Dib, L
    Makarem, J
    Hatoum, H
    Kanj, AR
    El-Hajj Fuleihan, G
    BONE, 2006, 38 (03) : S66 - S66
  • [27] Follistatins, activins and inhibins during osteoporosis therapy with denosumab or zoledronate and after their discontinuation
    Anastasilakis, Athanasios D.
    Makras, Polyzois
    Polyzos, Stergios A.
    Kumar, Ajay
    Kalra, Bhanu
    Mantzoros, Christos S.
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 2288 - 2293
  • [28] Denosumab for cancer-related bone loss
    Dell'Aquila, Emanuela
    Armento, Grazia
    Iuliani, Michele
    Simonetti, Sonia
    D'Onofrio, Loretta
    Zeppola, Tea
    Madaudo, Cristina
    Russano, Marco
    Citarella, Fabrizio
    Ribelli, Giulia
    Pantano, Francesco
    Vincenzi, Bruno
    Tonini, Giuseppe
    Santini, Daniele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (11) : 1261 - 1274
  • [29] Denosumab: RANKL inhibition in the management of bone loss
    Hamdy, N. A. T.
    DRUGS OF TODAY, 2008, 44 (01) : 7 - 21
  • [30] Effect of risedronate on bone loss at discontinuation of denosumab
    Laroche, Michel
    Couture, Guillaume
    Ruyssen-Witrand, Adeline
    Constantin, Arnaud
    Degboe, Yannick
    BONE REPORTS, 2020, 13